677 related articles for article (PubMed ID: 26604640)
1. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
[TBL] [Abstract][Full Text] [Related]
3. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
4. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation.
Ponziani FR; Zocco MA; D'Aversa F; Pompili M; Gasbarrini A
World J Gastroenterol; 2017 Jul; 23(25):4491-4499. PubMed ID: 28740337
[TBL] [Abstract][Full Text] [Related]
5. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
Bajaj JS
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
[TBL] [Abstract][Full Text] [Related]
6. Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis.
Shamsaddini A; Gillevet PM; Acharya C; Fagan A; Gavis E; Sikaroodi M; McGeorge S; Khoruts A; Albhaisi S; Fuchs M; Sterling RK; Bajaj JS
Gastroenterology; 2021 Aug; 161(2):508-521.e7. PubMed ID: 33857456
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome.
Bruzzese E; Pesce M; Sarnelli G; Guarino A
Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):753-760. PubMed ID: 29897844
[TBL] [Abstract][Full Text] [Related]
8. Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.
Chen YX; Lai LN; Zhang HY; Bi YH; Meng L; Li XJ; Tian XX; Wang LM; Fan YM; Zhao ZF; Han DW; Ji C
World J Gastroenterol; 2016 Mar; 22(10):2949-59. PubMed ID: 26973391
[TBL] [Abstract][Full Text] [Related]
9. Is treating the gut microbiome the key to achieving better outcomes in cirrhosis?
Hatton G; Shawcross DL
Expert Rev Gastroenterol Hepatol; 2019 Jan; 13(1):1-2. PubMed ID: 30791837
[No Abstract] [Full Text] [Related]
10. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiota-related complications in cirrhosis.
Gómez-Hurtado I; Such J; Sanz Y; Francés R
World J Gastroenterol; 2014 Nov; 20(42):15624-31. PubMed ID: 25400446
[TBL] [Abstract][Full Text] [Related]
12. Durability of rifaximin response in hepatic encephalopathy.
Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
[TBL] [Abstract][Full Text] [Related]
13. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
[TBL] [Abstract][Full Text] [Related]
15. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease.
Lopetuso LR; Napoli M; Rizzatti G; Gasbarrini A
Expert Opin Investig Drugs; 2018 Jun; 27(6):543-551. PubMed ID: 29865875
[TBL] [Abstract][Full Text] [Related]
16. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.
Vlachogiannakos J; Viazis N; Vasianopoulou P; Vafiadis I; Karamanolis DG; Ladas SD
J Gastroenterol Hepatol; 2013 Mar; 28(3):450-5. PubMed ID: 23216382
[TBL] [Abstract][Full Text] [Related]
17. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis.
Hanouneh MA; Hanouneh IA; Hashash JG; Law R; Esfeh JM; Lopez R; Hazratjee N; Smith T; Zein NN
J Clin Gastroenterol; 2012 Sep; 46(8):709-15. PubMed ID: 22878533
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiota: its role in hepatic encephalopathy.
Rai R; Saraswat VA; Dhiman RK
J Clin Exp Hepatol; 2015 Mar; 5(Suppl 1):S29-36. PubMed ID: 26041954
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota and host metabolism in liver cirrhosis.
Usami M; Miyoshi M; Yamashita H
World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study.
Lv XY; Ding HG; Zheng JF; Fan CL; Li L
World J Gastroenterol; 2020 Jan; 26(2):199-218. PubMed ID: 31988585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
